InspireMD Inc NSPR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
InspireMD to Announce Third Quarter 2026 Financial Results
InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference
InspireMD Reports Second Quarter 2026 Financial Results
InspireMD to Announce Second Quarter 2026 Financial Results
FDA Approves InspireMD's Application to Initiate Study of Neuro Protection System — Update
InspireMD Withdraws Guidance, Recalls CGuard Prime
Trading Information
- Previous Close Price
- $0.64
- Day Range
- $0.63–0.63
- 52-Week Range
- $0.44–2.16
- Bid/Ask
- $0.62 / $0.65
- Shares Outstanding
- 46.49M
- Market Cap
- $29.09M
- Volume/Avg
- 973 / 164,984
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.79
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 127
- Website
- https://www.inspiremd.com
Valuation
Metric | NSPR |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.95 |
Price/Sales | 4.79 |
Price/Cash Flow | — |
Price/Earnings
NSPR
Financial Strength
Metric | NSPR |
|---|---|
Quick Ratio | 3.40 |
Current Ratio | 3.80 |
Interest Coverage | — |
Quick Ratio
NSPR
Profitability
Metric | NSPR |
|---|---|
Return on Assets (Normalized) | −74.33% |
Return on Equity (Normalized) | −97.75% |
Return on Invested Capital (Normalized) | −93.35% |
Return on Assets
NSPR
Medical Devices Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Abbott Laboratories ABT | LOCK|^TDmd?> | LOCK|&L&t | $197B | |||
| Medtronic PLC MDT | LOCK|>?Hy%^% | LOCK|?$J$ | $134B | |||
| Stryker Corp SYK | LOCK|&M<!^N# | LOCK|s<h | $128B | |||
| Boston Scientific Corp BSX | LOCK|d$ZdJ^ | LOCK|y<my | $65B | |||
| Edwards Lifesciences Corp EW | LOCK|#M^#ww&y | LOCK|W%$JK | $58B | |||
| GE HealthCare Technologies Inc Common Stock GEHC | LOCK|F<g!Kpb | LOCK|K^% | $38B | |||
| DexCom Inc DXCM | LOCK|D^hQJlH& | LOCK|&s@s^ | $31B | |||
| Koninklijke Philips NV ADR PHG | LOCK|?T | LOCK|y<! | $30B | |||
| Steris PLC STE | LOCK|?zdQ^s | LOCK|>Hmr$ | $25B | |||
| Zimmer Biomet Holdings Inc ZBH | LOCK|@#gX>f@q | LOCK|b%> | $20B |
United States